Welcome to our dedicated page for Astellas Pharma news (Ticker: ALPMY), a resource for investors and traders seeking the latest updates and insights on Astellas Pharma stock.
News for ASTELLAS PHARMA UNSP/ (ALPMY) centers on the activities of Astellas Pharma Inc., a global life sciences company active in medicinal and botanical manufacturing and pharmaceutical development. Company press releases highlight developments across oncology, ophthalmology, urology, immunology and women’s health, as well as collaborations with partners, startups and academic institutions.
Investors and observers following ALPMY-related news will see frequent oncology updates. Recent items include long-term overall survival data for XTANDI (enzalutamide) in metastatic hormone-sensitive prostate cancer from the ARCHES and ENZAMET trials, and new analyses of PADCEV (enfortumab vedotin) in locally advanced or metastatic urothelial carcinoma. Astellas also announces its broader oncology presence at major meetings such as the ASCO Annual Meeting, where it presents multiple abstracts on approved therapies and pipeline programs, including a selective protein degrader targeting KRAS G12D.
Ophthalmology news features IZERVAY (avacincaptad pegol intravitreal solution), a C5 inhibitor for geographic atrophy secondary to age-related macular degeneration in the United States. Astellas reports new data from the GATHER Phase 3 studies and related analyses at ophthalmology congresses, covering biomarkers, disease mechanisms, patient experience and imaging-based structure–function relationships.
News flow also covers strategic partnerships and ecosystem-building initiatives. Examples include agreements with the Korea Institute of Startup and Entrepreneurship Development and Mitsubishi Research Institute to support drug-discovery startups in Korea and Japan, the Astellas Future Innovator Prize at MBC BioLabs for early-stage biotech companies, and a planned joint venture with YASKAWA Electric Corporation to develop a cell therapy manufacturing platform using the Maholo robot. Additional releases describe patient-centric campaigns such as Patient Advocacy Organization (PAO) Action Week and governance updates on nominees for the Board of Directors. Together, these news items provide a view into Astellas’ research focus, collaborations, patient engagement and corporate oversight relevant to ALPMY.
Astellas Pharma has released findings from two studies and a sleep survey that highlight the prevalence of vasomotor symptoms (VMS) during menopause and their disruptive effects on sleep. Approximately 34% of postmenopausal women in the U.S. experience moderate-to-severe VMS, with 61% reporting sleep disturbances. The studies underscore the need for new treatment options for VMS, given their negative impact on women's quality of life. These findings will be presented at the North American Menopause Society's 2020 Virtual Annual Meeting.
Astellas Pharma and Seattle Genetics announced that their phase 3 trial of PADCEV (enfortumab vedotin-ejfv) achieved its primary endpoint, demonstrating a significant improvement in overall survival for patients with locally advanced or metastatic urothelial cancer compared to chemotherapy. Specifically, the trial showed a 30% reduction in the risk of death (HR=0.70; p=0.001) and a 39% reduction in the risk of disease progression (HR=0.61; p<0.00001). Results will be submitted to the FDA for confirmatory approval and are intended to support global registrations.